Agenda

The 2010 BMT Tandem Meetings will convene February 24-28 at the Rosen Shingle Creek Convention Center in Orlando, Florida.  Parallel conferences held in conjunction with the main scientific meeting included:

         ■  Clinical Research Professionals and Data Managers – February 23-25
         ■  BMT CTN Coordinators – February 24

         ■  Pediatric BMT – February 25

         ■  BMT Center Administrators – February 25-26
         ■  BMT Pharmacists – February 26-27
         ■  Transplant Nursing – February 26-28 

         ■  BMT Medical Directors – February 27
         ■  Mid-Level Practitioners – February 27-28

In addition to the program highlights listed below, 90 speaker presentations were based on submitted abstracts.

WEDNESDAY – FEBRUARY 24

6:30 am  – Continental Breakfast

8:30 am – Opening Plenary Session   
Biology of Hematopoietic Cell Engraftment
Judith A. Shizuru, MD, PhD, Chair
   ■ Immunology of Engraftment
         Judith A. Shizuru, MD, PhD
   ■ Gaining Access to the Hematopoietic Stem Cell Niche
         Deepta Bhattacharya, MD
   ■ Clinical Correlate:  Haploidentical HCT for Primary Immunodeficiencies:  Obstacles and
      Anticipated Progress
        Marina Cavazzana-Calvo, MD, PhD

10:30 am
Selection of Adult Unrelated HSC Donors:  Beyond HLA (NMDP Session)
Dennis L. Confer, MD, Chair
   ■ Traditional Perspective on Non-HLA Factors in Donor Search
         Dennis L. Confer, MD
   ■ Creating a Donor Profile:  The Likelihood of a Successful Search, Procurement and Transplant
         Willis H. Navarro, MD

   ■ International Perspective on Donor Selection
         J.A. Madrigal, MD, PhD

Congenital Disorders of Ribosomal Biogenesis
Kathleen M. Sakamoto, MD, PhD, Chair
   ■ Clinical Aspects and Molecular Pathogenesis of Diamond Blackfan Anemia
          Kathleen M. Sakamoto, MD, PhD
   ■ Shwachman Diamond Syndrome:  Clinical and Molecular Features
          Akiko Shimamura, MD, PhD
   ■ Stem Cell Transplantation for Disease With Ribosomal Defects
         Stella M. Davies, MD, PhD

The Debate of the Century:  Should CNI + MTX be Considered Standard of Care for Prophylaxis of Acute GVHD?
Joseph H. Antin, MD, Chair
   ■ Con:  CNI + MTX Needs Improvement
          Corey S. Cutler, MD
   ■ Pro:  CNI + MTX is the Standard of Care Until Something is Proven to be Better
          Rainer Storb, MD

12:00 – BMT Tandem Meetings Symposium
Approaches to Graft Mobilization in the Autologous and Allogeneic Settings

4:45 pm
Oral Abstracts

6:30 pm
CIBMTR General Assembly 

6:45 pm

Mortimer M. Bortin Lecture
Alois A. Gratwohl, MD

The Evolution of Hematopoietic Stem Cell Transplantation:  A Darwinian View

7:30 pm
Welcome Reception

THURSDAY – FEBRUARY 25

7:15 pm – BMT Tandem Meetings Symposium
Transplant and Non-transplant Therapies for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma

8:30 am
Myelodysplastic Syndrome:  Improved Understanding
H. Joachim Deeg, MD, Chair
   ■ Non-Transplant Therapy
         Norbert Gattermann, MD, PhD
   ■ Hematopoietic Cell Transplantation for MDS
         Marcos DeLima, MD
   ■ Treatment Related MDS:  Models and Genetics
         Timothy A. Graubert, MD

Severe Sickle Cell Disease:  Pathophysiology and Therapy
Shalini Shenoy, MD, Co-Chair
   ■ Natural History of Acute and Chronic Organ Injury in Sickle Cell Disease
         George Buchanan, MD
   ■ Medical Management of Sickle Cell Disease
         Mark Walters, MD
   ■ Stem Cell Transplantation for Sickle Cell Disease
         Shalini Shenoy, MD
   ■ Trajectory of Disease Progression in Adulthood:  The Case For Novel Interventions
         Lakshmanan Krishnamurthi, MD

10:30 am
Transplantation for Autoimmune Disease
Keith M. Sullivan, MD, Chair
   ■ Resetting the Immune System to Control Autoimmune Disease:  Preclinical and Clinical Transplant Experience
         Paolo Muraro, MD
   ■ Autologous Stem Cell Transplant for Autoimmune Disease:  The European Experience
         Alan Tyndall, MD 
   ■ Auto or Allo Grafts for Autoimmune Disease:  Opportunities and Challenges in Cross    Disciplinary Clinical Trials
         Keith M. Sullivan, MD

Cardiac Stem Cell Therapy
Joshua M. Hare, MD, Chair
   ■ MSC Therapy:  Clinical Applications, Mechanism of Action
         Joshua M. Hare, MD
   ■ Genetically Modified Cells
         Mark Sussman, MD
   ■ Cardiac Stem Cells
         Piero Anversa, MD

Approaches for HLA-Haploidentical Stem Transplantation
Ephraim J. Fuchs, MD, MBA, Chair
   ■  Natural Killer Cells:  Biology and Adoptive Immunotherapy

          Jeffrey S. Miller, MD

   ■  Haploidentical Stem Cell Transplantation After Myeloablative Conditioning
          Xiao-Jun Huang, MD

   ■  Haploidentical Stem Cell Transplantation After Non-Myeloablative Conditioning
          Ephraim J. Fuchs, MD, MBA

Haplo-Indentical Transplantation in Children
Ann Woolfrey, MD, Co-Chair
   ■ T-Replete Haplo-Identical HCT Pre-Transplant Tolerization
         Eva Guinan, MD
   ■ T-Replete Haplo-Identical HCT Post-Transplant Cylophosphamide
         Leo Luznik, MD
   ■ Reduced Intensity Haplo-Identical Transplant
         Rupert Handgretinger, MD
 

12:00 – BMT Tandem Meetings Symposium
Role of Hematopoietic Stem Cell Transplantation for Myeloma in the Era of Novel Therapeutic Agents

12:30 pm
Pediatric International Session and Luncheon 
Sandeep Soni, MD, Co-Chair
   ■ Challenges and Prospects for International Collaborations:  Developing Countries Perspectives
         Ricardo Pasquini, MD
   ■ Challenges and Prospects for International Collaborations:  EBMT Perspective
         Christina Peters, MD

1:45 pm
Immunotherapy for CNS Tumors
Sharon Gardner, MD, Co-Chair
   ■ Immunotherapy for CNS Tumors
         Sharon Gardner, MD
   ■ Adoptive Cellular Therapy for Brain Tumors
         Nabil Ahmed, MD
   ■ Molecularlya Targeted Vaccine Strategies for Adult and Pediatric Patients with Glioma
         Hideho Okada, MD, PhD

Biology and Treatment of Histiocytic Disorders
Alexandra Filipovich, MD, Co-Chair
   ■ Hemophagocytic Lymphohistiocytosis
         Alexandra Filipovich, MD
   ■ Macrophage Activation Syndrome
         Alexei Grom, MD
   ■ New Insights Into Longerhams Cell Histiocytosis
         Kenneth McClain, MD, PhD

3:30 pm
Long Term Consequences of Hematopoietic Stem Cell Transplantation:  Current State of the Science
K. Scott Baker, MD, MS, Co-Chair
   ■ Late Mortality and Burden of Morbidity after Allogeneic Hematopoietic Cell Transplantation
         Smita Bhatia, MD
   ■ Metabolic Syndrome and Cardiovascular Risk after Hematopoietic Cell Transplantation
         K. Scott Baker, MD, MS
   ■ Role of Genetic Susceptibility in the Development of Cardiac Complications after HCT
         Saro Armenian, MD

4:45 pm
Oral Abstracts

6:45 pm
Poster Session I

FRIDAY – FEBRUARY 26

7:15 am – BMT Tandem Meetings Symposium
Accrual to Clinical Trials in the Hematopoietic Stem Cell Transplantation Setting

8:30 am
Natural Killer Cells
Katharine C. Hsu, MD, PhD, Chair
   ■ Natural Killer Cell Licensing and Education
         Wayne Yokoyama, MD, PhD
   ■ Natural Killer Cells and Viral Immunity
         Marcus Altfeld, MD, PhD
   ■ Natural Killer Cells and Stem Cell Transplantation:  Impact of KIR/HLA Genotypes on HCT
      Outcomes
          Katharine C. Hsu, MD

10:30 am
Engineering T-Cells for Immunotherapy  (ISCT Session)
Edwin M. Horwitz, MD, PhD and Mary J. Laughlin, MD, Co-Chairs
   ■ Adoptive Transfer of Regulatory T-Cells in UCB Transplantation
         Claudio Brunstein, MD, PhD
   ■ Vaccine Primed and Ex-Vivo Activated T-Cells for Reconstitution of Immune Memory Following
      Autologous Stem Cell Transplant in Multiple Myeloma
         Bruce Levine, PhD
   ■ Lentiviral Modified Umbilical Cord Blood T-Cells for Allogeneic Transplant in HIV
         Bruce E. Torbett, PhD

Bronchiolitis Obliterans After HSCT:  An Increasingly Recognized Manifestation of Chronic GVHD

Steven Z. Pavletic, MD, Chair

   ■ Epidemiology and Pathogenesis of BO After HSCT
         Jason W. Chien, MD, MS
   ■ Bronchiolitis Obliterans After Lung Transplantation 

         Steven R. Duncan, MD
   ■ Clinical Assessment and Therapy of BO After HSCT

         Kirsten M. Williams, MD

6:30 pm
ASBMT Business Meeting

E. Donnall Thomas Lecture
Stanley R. Riddell, MD
Therapeutic T-cells:  The End of the Long Beginning

SATURDAY – FEBRUARY 27

7:15 am – BMT Tandem Meetings Symposium
Prevention and Treatment of Posttransplant Fungal Infections

8:30 am
Aplastic Anemia:  Pathophysiology and Treatment
Judith C. Marsh, MD, Chair
   ■ Pathophysiology of Aplastic Anemia
         Neal S. Young, MD
   ■ Outcomes After Immunosuppressive Therapy
         Judith C. Marsh, MD
   ■ Recent Advances in Stem Cell Transplantation
         Andrea P. Bacigalupo, MD

10:30 am
Graft Failure and Engraftment in Cord Blood Transplantation
Vanderson Rocha, MD, PhD, Chair
   ■ Homing and Engraftment of Cord Blood Cells:  The Biology Perspective
         Hal E. Broxmeyer, PhD
   ■ Risk Factors for Engraftment and Treatment Options for Graft Failure
          Vanderson Rocha, MD, PhD
   ■ New Approaches to Improve Engraftment in Cord Blood Transplantation
          John E. Wagner, MD

Immune Reconstitution:  How It Should Work, What's Broken and Why it Matters
Ronald E. Gress, MD, Chair
   ■ Immune Reconstitution:  Cells, Pathways and Cytokines
         Ronald E. Gress, MD
   ■ Restrictions on Immune Reconstitution
         William R. Drobyski, MD
   ■ Immune Reconstitution and GVHD 
          Stephen G. Emerson, MD, PhD

Understanding Gaps in Access to Hematopoietic Cell Transplantation 
J. Douglas Rizzo, MD, MS, Chair
   ■ Access to HCT in the US:  Socioeconomic and Racial Barriers
          Navneet S. Majhail, MD
   ■ Access to Hematopoietic Stem Cell Transplantation:  A Global Perspective
          Alois A. Gratwohl, MD
   ■ Autologous HCT for Breast Cancer:  Can We Better Explain the Decline?
          David H. Howard, PhD

12:00 – BMT Tandem Meetings Symposium
Bone Marrow versus Peripheral Blood in HCT

1:30 pm
BMT Medical Directors Conference

SUNDAY – FEBRUARY 28

6:30 am  – Continental Breakfast

8:00 am
Relapse After Allogeneic Hematopoietic Cell Therapy
Michael R. Bishop, MD, Chair

   ■ Current Understanding of the Roles of T and Natural Killer Cells in the Graft-versus-Leukemia

      Effect
          Marcel R.M. van den Brink, MD, PhD
   ■ Strategies and Options for Recurrent Disease Following Allogeneic Stem Cell Transplantation
         David L. Porter, MD
   ■ Summary Report on the First International Workshop on the Biology, Prevention and Treatment
      of Relapse After Allogeneic Hematopoietic Cell Transplantation
          Sergio A. Giralt, MD

10:00 am
Oral Abstracts

12:00 pm 

Current Challenges in Chronic GVHD
Gerald P. Socie, MD, PhD, Chair
   ■ Improving Human Pathophysiology Knowledge

          Jerome Ritz, MD

   ■ Clinical Spectrum and Disease Severity

          Gerald P. Socie, MD, PhD

   ■ Prophylaxis and Treatment:  What's Next?

          Paul J. Martin, MD